- 70-acre site that combines state-of-the-art R&D facilities with flexible, multi-product manufacturing capabilities. Andover is strategically positioned as a fully integrated site, serving as a vital cog in both Pfizer's WRD and Pfizer Global Supply network
- In 2007, Andover became the first biotechnology facility in New England to receive OSHA's Voluntary Protection Program (VPP) certification for its work in building a culture of safety
Functions: Drug Safety R&D (DSRD), BioTherapeutic Pharmaceutical Sciences: Bioprocess R&D (BRD), Analytical R&D (ARD), Pharmaceutical R&D (PhRD), Comparative Medicine (CM), Pharmocokinetics, Dynamics & Metabolism (PDM), Global Chemistry, Manufacturing and Controls (GCMC)
Primary Therapeutic Areas: Services multiple therapeutic areas; focused on biological compounds
The Andover campus consists of eight buildings which house laboratories, clinical and commercial manufacturing suites, purification and support areas and a clinical Drug Product manufacturing facility (LDM).
The commercial manufacturing areas produce BeneFIX®, Coagulation Factor IX (Recombinant) and bone morphogenetic protein (rhBMP). Andover is the global production facility for polysaccharides, components of Prev(e)nar-13, Pneumococcal 13-valent Conjugate Vaccine (Diptheria CRM197 Protein). Andover's Building B is approved as a multiproduct facility, allowing clinical and commercial products to be manufactured simultaneously and has been designated as the launch site for Pfizer’s mAb drug substances.